The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Details for Australian Patent Application No. 2003217930 (hide)

International Classifications

Event Publications

31 July 2003 Complete Application Filed

Priority application(s): 60/444,265 30.01.03 US; 60/361,859 04.03.02 US; 60/370,398 05.04.02 US

30 October 2003 Application Open to Public Inspection

Published as AU-A-2003217930

2 October 2008 Alteration of Name

The name of the applicant has been altered to MedImmune, LLC

19 March 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.